Lung Cancer Clinical Trials in New York State

Showing 361-380 of 594 trials

Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer

NCT03090737

A study to evaluate the safety of Nivolumab in participants with advanced or metastatic non-small cell lung cancer

Bristol-Myers Squibb129 participantsStarted Jun 2017

Birmingham, Alabama, United States • Los Angeles, California, United States • Billings, Montana, United States +14 more locations

TERMINATEDPhase 362 miles

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

NCT00858364

This is a study in patients with chemotherapy induced anemia receiving multi-cycle chemotherapy for the treatment of stage IV non-small cell lung cancer (NSCLC). The primary objective of the study is to demonstrate that overall survival (OS) is not worse in participants on darbepoetin alfa treated to a hemoglobin ceiling of 12.0 g/dL compared to participants treated with placebo.

Non-Small Cell Lung CancerAnemiaCancer+1 more

Amgen2,549 participantsStarted Jul 2009

Anniston, Alabama, United States • Birmingham, Alabama, United States • Anchorage, Alaska, United States +563 more locations

Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Lung Cancer Trials in Other Cities

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

A Study of LY3023414 in Participants With Advanced Cancer

Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer

Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC

Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices as Adjunctive Oncology Treatment

Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin

PEN-866 in Patients With Advanced Solid Malignancies

Stereotactic Body Radiotherapy Versus Conventional Radiotherapy in Medically-Inoperable Non-Small Lung Cancer Patients

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)

First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC

REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer

Other Conditions in New York State